KOS PHARMACEUTICALS
Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The companyโs principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos๏ฟฝ... ๏ฟฝ๏ฟฝ strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The company currently markets Niaspan, Advicor, Azmacort, Cardizem LA, Teveten and Teveten HCT. Kos has a strong and growing research and development pipeline including proprietary drug delivery technologies in solid-dose, inhalation and aerosol metered-dose device administration to help fuel sustained, organic sales growth into the future.
KOS PHARMACEUTICALS
Social Links:
Industry:
Health Care Medical Pharmaceutical
Founded:
1988-01-01
Address:
Cranbury, New Jersey, United States
Country:
United States
Total Employee:
1001+
Status:
Active
Total Funding:
0
Similar Organizations
Acuity Pharmaceuticals
Acuity Pharmaceuticals product-focused ophthalmic pharmaceutical company applying its proprietary technology to the treatment.
Eleison Pharmaceuticals
Eleison Pharmaceuticals acquires, develops, and commercializes clinical stage drug candidates for "orphan" cancers.
Investors List
Bill Pruitt
Bill Pruitt investment in Seed Round - KOS Pharmaceuticals
More informations about "KOS Pharmaceuticals"
Kos Pharmaceuticals, Inc. -- Company History
Kos Pharmaceuticals, Inc. specializes in the development of proprietary pharmaceutical products for the treatment of cardiovascular and respiratory disease through the reformulation of โฆSee details»
Abbott to acquire Kos Pharmaceuticals for $3.7 billion - Reliable โฆ
Abbott and Kos Pharmaceuticals Inc. on November 6 announced a definitive agreement for Abbott to acquire Kos for $78 per share in cash, for a total transaction value of $3.7 billion, net โฆSee details»
KOS Pharmaceuticals, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for KOS Pharmaceuticals, Inc. of Cranbury, NJ. Get the latest business insights from Dun & Bradstreet.See details»
Kos Pharmaceuticals 2025 Company Profile: Valuation, โฆ
Kos Pharmaceuticals General Information Description. Manufacturer of prescription products for the treatment of chronic cardiovascular diseases. โฆSee details»
Kos Pharmaceuticals Company Profile | Management and
Kos Pharmaceuticals Profile and History. Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and โฆSee details»
KOS PHARMACEUTICALS, INC. - SEC.gov
KOS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) FLORIDA : 65-0670898 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. โฆSee details»
Kos Pharmaceuticals - Ownership and Business Overview - Mergr
Nov 6, 2006 Kos Pharmaceuticals was founded in 1988. Life Science M&A Summary in 2006 Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2006 .See details»
KOS Pharmaceuticals - Funding, Financials, Valuation & Investors
Jan 1, 2004 KOS Pharmaceuticals is a pharmaceutical company that manufactures prescription products. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log โฆSee details»
Kos Pharmaceuticals Profile: Summary โข OpenSecrets
Kos Pharmaceuticals organization profile. Contributions in the 2022 cycle: $100. Lobbying in 2022: $0. Outside Spending in the 2022 cycle: $0.See details»
Organization | Kos Pharmaceuticals
Kos Pharmaceuticals Report issue. For profit Phase 4. Founded: Cranbury NJ United States ... Organization Overview. First Clinical Trial. 2000 NCT00307307. First Marketed Drug. None ...See details»
KOS Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical
Explore KOS Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 11 clinical trials, 7 news, and 18 literature, Disease Domain ...See details»
Kos Pharmaceuticals, Inc. - SEC.gov
Kos Pharmaceuticals, Inc. 1 Cedar Brook Drive Cranbury NJ 08512-3618 (609) 495-0500 ... โThis is an opportune time to become a part of another fast-growing organization like Abbott with the โฆSee details»
Office of Public Affairs | Kos Pharmaceuticals to Pay More Than โฆ
Dec 7, 2010 From 2002 to 2004, Kos made a series of payments to the two doctors or a third party intermediary in the form of โsponsorshipโ of continuing medical education classes โฆSee details»
Kos Pharmaceuticals, Inc. - SEC.gov
The aggregate market value of Kos Pharmaceuticals, Inc. Common Stock, $.01 par value, held by non-affiliates, computed by reference to the price at which the stock was sold as of June 30, โฆSee details»
Kos Pharmaceuticals Inc. Information - CareersInPharmaceutical.com
KOS Pharmaceuticals is concentrating on the cardiovascular and respiratory markets because of their extraordinary size and growth, because physician prescribing patterns in these markets โฆSee details»
Kos Pharmaceuticals, Inc. | Greenhill & Co
Nov 6, 2006 Kos Pharmaceuticals, Inc. 06-Nov-06. $4.2 billion. Target: Kos Pharmaceuticals, Inc. Acquiror: Abbott Laboratories. Advised Kos Pharmaceuticals, Inc., a specialty โฆSee details»
KOS Pharmaceuticals - Tech Stack, Apps, Patents & Trademarks
The intellectual property of KOS Pharmaceuticals includes 7 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Additionally, KOS โฆSee details»
KOS PHARMACEUTICALS Careers and Employment - Indeed
Find out what works well at KOS PHARMACEUTICALS from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. ... My managers were โฆSee details»
Kos Pharmaceuticals gets $50 million boost
Dec 20, 1999 Kos said it will also be able to aggressively promote its current range of products: Niaspan (niacin), which was recently approved in the USA for the elevation of protective high โฆSee details»
Simplification for success: Rewiring the biopharma operating model
Mar 21, 2025 Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different โฆSee details»